Gastrointestinal (GI) diseases can be complex, debilitating and life-changing. That is why Takeda and our collaboration partners are committed to improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for over 25 years.

Takeda is leading areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our GI research & development team is also exploring treatments in celiac disease, advanced liver disease and microbiome therapies. We strive to understand the causes of these diseases and develop therapies that can ultimately advance how patients manage their condition.
# SUMMARY

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Edito ................................................................. 4</td>
</tr>
<tr>
<td>2</td>
<td>The board ............................................................ 5</td>
</tr>
<tr>
<td>3</td>
<td>Partners .............................................................. 6</td>
</tr>
<tr>
<td>4</td>
<td>Exhibition plan ..................................................... 7</td>
</tr>
<tr>
<td>5</td>
<td>Program</td>
</tr>
<tr>
<td>6</td>
<td>• Thursday, September 5&lt;sup&gt;th&lt;/sup&gt; ......................... 8 - 9</td>
</tr>
<tr>
<td></td>
<td>• Friday, September 6&lt;sup&gt;th&lt;/sup&gt; .............................. 10 - 11</td>
</tr>
<tr>
<td></td>
<td>• Saturday, September 7&lt;sup&gt;th&lt;/sup&gt; ............................ 12</td>
</tr>
<tr>
<td>7</td>
<td>Poster sessions .................................................... 14 - 21</td>
</tr>
<tr>
<td>8</td>
<td>Practical information ............................................ 23</td>
</tr>
</tbody>
</table>
Dear Friends,

Eighteen very intense years separate ICDS 2002 and ICDS 2019 in Paris. Over this period, interest for coeliac disease has been blooming worldwide and ICDS has met formidable success across Europe, in the US and recently in India. Considerable efforts have been invested and have succeeded in unravelling the wide geographic distribution and increasing incidence of coeliac disease, in describing its highly versatile and changing clinical presentation, in refining diagnostic approaches. Pathophysiological studies have considerably progressed, and translation into innovative and rationale-based strategies has been initiated. New therapeutic approaches will be soon available outside gluten free diet. Beyond coeliac disease, the possible impact of dietary gluten on human health is raising considerable concern and interrogation on the reality and possible mechanisms of non-coeliac cases of gluten-driven pathology.

With the ISSCD board and of the ICDS 2019 scientific committee, we intend to make the 18th ICDS an outstanding forum for sharing expanding knowledge, for promoting education in coeliac disease and related disorders. We intend to encourage many discussions, to delineate future challenges in the field and to build and foster international cooperation. We expect that Paris will be ideal to combine first class science with pleasurable food and many romantic or cultural promenades.

Christophe Cellier and Nadine Cerf Bensussan for the Organising committee.
The International Society for the Study of Celiac Disease

**THE BOARD**

Pr David S Sanders  
*President of the ISSCD*

Pr Christoph Cellier  
Dr Govind Makharia  
Pr Ricardo Troncone  
Pr Knut Lundin  
Dr Bana Jabri  
Dr Luisa Mearin

**FACULTY**

Valerie Abadie  
Dr. Daniel Agardh  
Bob Anderson  
Carin Andren Aronsson  
Renata Auricchio  
Julio Bai  
Julie Bruneau  
Carlo Catassi  
Angel Cebolla  
Christophe Cellier  
Nadine Cerf-Bensussan  
Juliana Cerqueira  
Fabienne Charbit-Henriton  
Carolina Ciacci  
Sascha Cording  
Hilary Croft  
Prasenjit Das  
Fleur Du Pre  
Knut E. A. Lundin  
Linn Egggesbo  
Luca Elli  
Alain Fischer  
Peter Green  
Marios Hadjivassiliou  
Melinda Hardy  
Olivier Hermine  
Bana Jabri  
Iris Jonkers  
Pauline Jouet  
Sherine Khater  
Chaitan Khosla  
Mikael Knip  
Tunde Koltai  
Ilma Korponay-Szabo  
Frits Koning  
Alain Lachaux  
Benjamin Lebwohl  
Dan Leffler  
Ida Lindeman  
Katri Lindfors  
Elena Lionetti  
Jonas Ludvigsson  
Ludvig M. Sollid  
Govind Makharia  
Markku Mäki  
Philippe Marteau  
Maria Luisa Mearin  
Thierry Molina  
Chris Mulder  
Joseph Murray  
Hugo Penny  
Jean-Marie Peron  
Lluis Quintana-Murci  
Gabriel Rahmi  
Maxime-Dominique Rouvroye  
David Sanders  
Katharina Scherf  
Detlef Schuppan  
David Sibon  
Harry Sokol  
Patrick Tounian  
Riccardo Troncone  
Nick Trott  
Christel Turcat  
Heidi Urwin  
Elena Verdu  
Umberto Volta  
David Wraith  
Maria Zorro  
Stephanie Zühlke

**REVIEWERS**

ICDS 2019 would like to express its special thanks to the abstract reviewers, which played an important role in the appreciation of the research abstracts.

Dr. Daniel Agardh  
Dr. Bob Anderson  
Dr. Renata Auricchio  
Pr. Julio Bai  
Pr. Christophe Cellier  
Dr. Nadine Cerf-Bensussan  
Pr. Carolina Ciacci  
Dr. Paula Crespo  
Pr. Peter Green  
Dr. Stefano Guandalini  
Pr. Frits Koning  
Dr. Kalle Kurppa  
Dr. Benjamin Lebwohl  
Pr. Knut E. A. Lundin  
Pr. Ludvig M. Sollid  
Pr. Govind Makharia  
Pr. Maria Luisa Maerin  
Pr. Chris Mulder  
Pr. Joseph Murray  
Pr. David Sanders  
Pr. Detlef Schuppan  
Pr. Riccardo Troncone  
Pr. Umberto Volta  
Dr. Margreet Wessels
**THURSDAY, SEPTEMBER 5TH, 2019**

**SCIENTIFIC FORUM - ROOM SCENE - LEVEL 0**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 - 08:30 am</td>
<td>Welcome remarks</td>
</tr>
<tr>
<td>08:30 - 10:00 am</td>
<td><strong>Update in celiac disease diagnosis</strong></td>
</tr>
<tr>
<td></td>
<td>Chairpersons: David Sanders, Sheffield, United-Kingdom; Alain Lachaux, Lyon, France</td>
</tr>
<tr>
<td>08:30 - 10:00 am</td>
<td>Celiac disease diagnosis in adults: update</td>
</tr>
<tr>
<td></td>
<td>Knut E. A. Lundin, Oslo, Norway</td>
</tr>
<tr>
<td>08:50 - 09:10 am</td>
<td>Celiac diagnosis in children: new ESPGHAN criteria guidelines</td>
</tr>
<tr>
<td></td>
<td>Riccardo Troncone, Naples, Italy</td>
</tr>
<tr>
<td>09:10 - 09:30 am</td>
<td>Mass screening vs targeted screening: update</td>
</tr>
<tr>
<td></td>
<td>Maria Luisa Mearin, Leiden, Netherlands</td>
</tr>
<tr>
<td>09:30 - 10:00 am</td>
<td>Phospholipid profile at 4 months of age predicts the onset of celiac disease in at risk infants.</td>
</tr>
<tr>
<td></td>
<td>Renata Auricchio, Naples, Italy</td>
</tr>
<tr>
<td>09:50 - 10:00 am</td>
<td>How long should children with a first-degree celiac relative be followed and screened?</td>
</tr>
<tr>
<td></td>
<td>Ilma Korponay-Szabo, Debrecen, Hungary</td>
</tr>
<tr>
<td>10:00 - 10:30 am</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10:30 - 12:00 pm</td>
<td><strong>Omnics approaches in celiac disease</strong></td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Iris Jonkers, Groningen, Netherlands; Nadine Cerf-Bensussan, Paris, France</td>
</tr>
<tr>
<td>10:30 - 12:00 pm</td>
<td>Genetic and environmental factors driving immune response variation in humans</td>
</tr>
<tr>
<td></td>
<td>Luis Quintana-Murci, Paris, France</td>
</tr>
<tr>
<td>11:00 - 11:30 am</td>
<td>Understanding celiac disease from a genetic point of view</td>
</tr>
<tr>
<td></td>
<td>Iris Jonkers, Groningen, Netherlands</td>
</tr>
<tr>
<td>11:30 - 12:00 pm</td>
<td>Independent and cumulative effects of celiac disease susceptibility loci differentially contribute to various clinical phenotypes</td>
</tr>
<tr>
<td></td>
<td>Juliana Cerqueira, Tampere, Finland</td>
</tr>
<tr>
<td>11:40 - 12:00 pm</td>
<td>Kinetics and transcriptomics of gluten-specific T cells in blood after gluten challenge</td>
</tr>
<tr>
<td></td>
<td>Stephanie Zühike, Oslo, Norway</td>
</tr>
<tr>
<td>11:50 - 12:00 pm</td>
<td>NMR based Metabonomics of Intestinal Mucosal Biopsies, Blood and Urine to Identify Potential Biomarker(s) for Celiac Disease</td>
</tr>
<tr>
<td></td>
<td>Govind Makharia, New Delhi, India</td>
</tr>
<tr>
<td>12:15 - 01:45 pm</td>
<td>Lunch &amp; Symposium sponsored by Provention Bio</td>
</tr>
<tr>
<td>12:15 - 01:15 pm</td>
<td><strong>Interleukin-15 (IL-15) in celiac disease and therapeutic potential of the anti-IL-15 antibody PRV-015/AMG 714</strong></td>
</tr>
<tr>
<td></td>
<td>Chairperson: David Sanders, Sheffield, United Kingdom</td>
</tr>
<tr>
<td>12:15 - 01:15 pm</td>
<td>Unmet need in celiac disease - Patients’ views</td>
</tr>
<tr>
<td></td>
<td>Marilyn Geller, Los Angeles, United States</td>
</tr>
<tr>
<td>12:30 - 01:15 pm</td>
<td>Role of interleukin 15 (IL-15) in celiac disease</td>
</tr>
<tr>
<td></td>
<td>Bana Jabri, Chicago, United States</td>
</tr>
<tr>
<td>12:45 - 01:15 pm</td>
<td>Targeting IL-15 in celiac disease (results of CELIM-NRCD-001 trial)</td>
</tr>
<tr>
<td></td>
<td>Markku Mäki, Tampere, Finland</td>
</tr>
<tr>
<td>01:00 - 01:30 pm</td>
<td>Targeting IL-15 in refractory celiac disease (results of CELIM-RCD-002 trial)</td>
</tr>
<tr>
<td></td>
<td>Christophe Cellier, Paris, France</td>
</tr>
<tr>
<td>01:15 - 01:30 pm</td>
<td>Next steps for anti-IL-15 (PRV-015/AMG 714) as a therapeutic for celiac disease</td>
</tr>
<tr>
<td></td>
<td>Francisco Leon, Washington DC, United States</td>
</tr>
<tr>
<td>01:30 - 01:45 pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>01:45 - 03:30 pm</td>
<td>Pathogenesis I</td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Ludvig M.Sollid, Oslo, Norway</td>
</tr>
<tr>
<td>01:45 - 02:10 pm</td>
<td>Adaptive immunity in celiac disease: from pathogenesis to diagnosis?</td>
</tr>
<tr>
<td></td>
<td>Ludvig M.Sollid, Oslo, Norway</td>
</tr>
<tr>
<td>02:10 - 02:35 pm</td>
<td>Innate immunity in celiac disease?</td>
</tr>
<tr>
<td></td>
<td>Bana Jabri, Chicago, United States</td>
</tr>
<tr>
<td>02:35 - 03:00 pm</td>
<td>From autoimmunity to lymphomagenesis in celiac disease</td>
</tr>
<tr>
<td></td>
<td>Nadine Cerf-Bensussan, Paris, France</td>
</tr>
<tr>
<td>03:00 - 03:30 pm</td>
<td>Tissue alarmins and adaptive cytokine induce dynamic and distinct transcriptional responses in tissue-resident intraepithelial cytotoxic T lymphocytes</td>
</tr>
<tr>
<td></td>
<td>Maria Zorro, Groningen, Netherlands</td>
</tr>
<tr>
<td>03:10 - 03:30 pm</td>
<td>The intraepithelial, tcr repertoire is more diverse in celiac disease patients than in healthy subjects</td>
</tr>
<tr>
<td></td>
<td>Linn Eggesbo, Oslo, Norway</td>
</tr>
<tr>
<td>03:20 - 03:45 pm</td>
<td>B-cell tolerance and antibody production to the celiac disease</td>
</tr>
<tr>
<td></td>
<td>autoantigen transglutaminase 2 (TG2)</td>
</tr>
<tr>
<td></td>
<td>Fleur Du Pre, Oslo, Norway</td>
</tr>
<tr>
<td>03:30 - 04:00 pm</td>
<td>Coffee break</td>
</tr>
<tr>
<td>04:00 - 04:40 pm</td>
<td>Keynote lecture</td>
</tr>
<tr>
<td></td>
<td>Chairperson: Bana Jabri, Chicago, United States</td>
</tr>
<tr>
<td>04:00 - 04:40 pm</td>
<td>Autoimmunity: lessons from human immunodeficiencies</td>
</tr>
<tr>
<td></td>
<td>Alain Fisher, Paris, France</td>
</tr>
<tr>
<td>04:40 - 06:00 pm</td>
<td>Drink and Posters</td>
</tr>
</tbody>
</table>
## THURSDAY, SEPTEMBER 5TH, 2019
### CLINICAL FORUM - ROOM FORUM - LEVEL -1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
</table>
| 08:15 - 12:30 pm | **SNFGE French Symposium**  
Chairperson: Jean-Marie Peron, Toulouse, France                                              |                                                                                               |
| 08:20 - 10:00 am | **Maladie coeliaque : physiopathologie, diagnostic et traitement**  
Chairpersons: Jean-Marie Peron, Toulouse, France; Philippe Marteau, Paris, France               |                                                                                               |
| 08:20 - 08:40 am | Physiopathologie de la maladie coeliaque  
Bana Jabri, Chicago, United States                                                          |                                                                                               |
| 08:40 - 09:00 am | Physiopathologie des complications malignes de la maladie coeliaque  
Nadine Cerf-Bensussan, Paris, France                                                        |                                                                                               |
| 09:00 - 09:20 am | Diagnostic et traitement de la maladie coeliaque  
Christophe Cellier, Paris, France                                                           |                                                                                               |
| 09:20 - 09:40 am | Hypersensibilité au gluten : mythe ou réalité  
Sherine Khater, Paris, France                                                                |                                                                                               |
| 09:40 - 10:00 am | Diagnostic histologique des complications de la maladie coeliaque  
Julie Bruneau, Paris, France; Thierry Molina, Paris, France                               |                                                                                               |
| 10:00 - 10:30 am | **Coffee break**                                                                         |                                                                                               |
| 10:30 - 12:30 pm | **Maladies associées et nouveaux traitements**  
Chairpersons: Pauline Jouet, Paris, France; Patrick Tounian, Paris, France                 |                                                                                               |
| 10:30 - 10:50 am | Indication du régime sans gluten et autres régimes (FODMAPs)  
Pauline Jouet, Paris, France                                                               |                                                                                               |
| 10:50 - 11:10 am | Maladie coeliaque de l’enfant: spécificités et transition  
Alain Lachaux, Lyon, France                                                               |                                                                                               |
| 11:10 - 11:30 am | Intolérances alimentaires chez l’enfant  
Patrick Tounian, Paris, France                                                               |                                                                                               |
| 11:30 - 11:50 am | Maladies hépatiques et pancréatiques et maladie coeliaque  
Jean-Marie Peron, Toulouse, France                                                         |                                                                                               |
| 11:50 - 12:10 pm | Classification et traitement des lymphomes associés à la maladie coeliaque  
David Sibon, Paris, France                                                                |                                                                                               |
| 12:10 - 12:30 pm | Microbiote et physiopathologie de l’intestin grêle  
Philippe Marteau, Paris, France                                                             |                                                                                               |
| 12:30 - 01:45 pm | **Poster session**                                                                        |                                                                                               |
| 01:45 - 03:35 pm | **Epidemiological and diagnostic update in celiac disease**  
Chairpersons: Carlo Catassi, Ancona, Italy; Philippe Marteau, Paris, France                  |                                                                                               |
| 01:45 - 02:05 pm | The global village of celiac disease  
Carlo Catassi, Ancona, Italy                                                                   |                                                                                               |
| 02:05 - 02:25 pm | The Indian and Asian perspective  
Govind Makharia, New Delhi, India                                                              |                                                                                               |
| 02:25 - 02:45 pm | Diagnostic and biopsy strategy  
David Sanders, Sheffield, United-Kingdom                                                          |                                                                                               |
| 02:45 - 03:05 pm | Antibody negative villous atrophy  
Joseph Murray, Rochester, United States                                                          |                                                                                               |
| 03:05 - 03:20 pm | Making a diagnosis of celiac disease in children  
Maria Luisa Mearin, Leiden, Netherlands                                                        |                                                                                               |
| 03:20 - 03:35 pm | How to organise transition for young celiac?  
Carolina Ciacci, Salerno, Italy                                                                |                                                                                               |
| 03:35 - 04:00 pm | **Coffee break**                                                                          |                                                                                               |
| 04:00 - 05:40 pm | **Endoscopy and celiac disease**  
Chairpersons: Jean-Marie Peron, Toulouse, France; Gabriel Rahmi, Paris, France                 |                                                                                               |
| 04:00 - 04:20 pm | Videocapsule in celiac disease  
Luca Elli, Milano, Italy                                                                              |                                                                                               |
| 04:20 - 05:00 pm | Role of device assisted enteroscopy in celiac disease  
Sherine Khater, Paris, France                                                               |                                                                                               |
| 05:00 - 05:20 pm | Novel endoscopy recognition of celiac disease (magnification, NBI, BLI, etc)  
Gabriel Rahmi, Paris, France                                                                  |                                                                                               |
| 05:20 - 05:40 pm | Which work-up for suspicion of malignancy in celiac disease?  
Chris Mulder, Amsterdam, Netherlands                                                          |                                                                                               |
| 04:40 - 06:00 pm | **Drink and Posters**                                                                     |                                                                                               |
FRIDAY, SEPTEMBER 6TH, 2019

SCIENTIFIC FORUM - ROOM SCENE - LEVEL 0

<table>
<thead>
<tr>
<th>08:00 - 08:40 am</th>
<th>Keynote Lecture: The interplay between genetics and environment in type 1 diabetes</th>
<th>Mikael Knip, Helsinki, Finland</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:40 - 10:00 am</td>
<td>Epidemiology &amp; environmental triggers</td>
<td>Chairpersons: Daniel Agardh, Lund, Sweden; Elena Verdu, Ontario, Canada</td>
</tr>
<tr>
<td>08:40 - 09:00 am</td>
<td>Natural history of celiac disease: lessons from at risk pediatric cohorts</td>
<td>Daniel Agardh, Lund, Sweden</td>
</tr>
<tr>
<td>09:00 - 09:20 am</td>
<td>Mechanistic insight into the role of microbiota in intestinal inflammation</td>
<td>Harry Sokol, Paris, France</td>
</tr>
<tr>
<td>09:20 - 09:40 am</td>
<td>Environmental factors: update on the role of gut microbiota in celiac disease</td>
<td>Elena Verdu, Ontario, Canada</td>
</tr>
<tr>
<td>09:40 - 09:50 am</td>
<td>Metagenomic analysis of fecal virome identifies specific enteroviruses and adenoviruses as potential triggers of celiac disease autoimmunity in the TEDDY study</td>
<td>Kati Lindfors, Tampere, Finland</td>
</tr>
<tr>
<td>09:50 - 10:00 am</td>
<td>Gluten intake and risk of celiac disease</td>
<td>Carin Andreon Aronsson, Malmo, Sweden</td>
</tr>
<tr>
<td>10:00 - 10:30 am</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:00 pm</td>
<td>Pathogenesis II</td>
<td>Chairpersons: Frits Koning, Leiden, Netherlands; Detlef Schuppan, Mainz, Germany</td>
</tr>
<tr>
<td>10:30 - 11:00 am</td>
<td>Lessons from animal models in celiac disease</td>
<td>Valerie Abadié, Chicago, United States</td>
</tr>
<tr>
<td>11:00 - 11:30 am</td>
<td>Innovative approaches to investigate human gut immune cells in celiac disease?</td>
<td>Frits Koning, Leiden, Netherlands</td>
</tr>
<tr>
<td>11:30 - 12:00 pm</td>
<td>Characterisation of Clinical and Immune Reactivity to Barley and Rye Consumption in Children with Celiac Disease</td>
<td>Melinda Hardy, Melbourne, Australia</td>
</tr>
<tr>
<td>11:40 - 12:10 pm</td>
<td>Simultaneous transcriptional characterisation and clonal inference of disease-specific plasma cells in coeliac disease</td>
<td>Ida Lindeman, Oslo, Norway</td>
</tr>
<tr>
<td>12:10 - 12:20 pm</td>
<td>The genetic landscape of type II Refractory Celiac Disease and Enteropathy Associated T-Cell Lymphoma reveals recurrent activating mutations of the JAK1/STAT3 axis</td>
<td>Sascha Cording, Paris, France</td>
</tr>
<tr>
<td>12:20 - 01:35 pm</td>
<td>Lunch &amp; poster session</td>
<td></td>
</tr>
<tr>
<td>01:35 - 03:15 pm</td>
<td>Symposium sponsored by Takeda</td>
<td></td>
</tr>
<tr>
<td>03:15 - 03:45 pm</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>03:45 - 04:05 pm</td>
<td>The spectrum of gluten associated diseases</td>
<td>Chairpersons: Peter Green, New York, United States; Sheila Crowe, San Diego, United States</td>
</tr>
<tr>
<td>03:45 - 04:05 pm</td>
<td>Gluten hypersensitivity: myth and reality?</td>
<td>Peter Green, New York, United States</td>
</tr>
<tr>
<td>04:05 - 04:25 pm</td>
<td>Has gluten recently changed in composition or processing?</td>
<td>Katharina Scherl, Freising, Germany</td>
</tr>
<tr>
<td>04:25 - 04:45 pm</td>
<td>Extraintestinal manifestations of celiac disease or celiac disease associated diseases</td>
<td>Jonas Ludvigsson, Stockholm, Sweden</td>
</tr>
<tr>
<td>04:45 - 04:55 pm</td>
<td>Post-Mortem Immuno-Pathological Findings in the Cerebellum of Celiac Disease patients with concomitant Idiopathic Neurological Disorder</td>
<td>Maxine-Dominique Rouvroye, Amsterdam, Netherlands</td>
</tr>
<tr>
<td>04:55 - 05:05 pm</td>
<td>IgA anti-tTG co-localization for identification of Celiac Associated Liver Diseases</td>
<td>Prasenjit Das, New Delhi, India</td>
</tr>
</tbody>
</table>
| 05:05 - 06:00 pm | Drink and Posters 

Welcome and introduction
Dan Leffler, Boston, United States
Will there be a role for endoscopy and biopsy in the diagnosis of celiac disease in 10 years?
David Sanders, Sheffield, United Kingdom
Will we still be talking about the Gluten-Free diet in 2030?
Maureen Leonard, Boston, United States
Will novel technologies revolutionise the way we monitor celiac disease?
Luca Ellì, Milano, Italy
Panel discussion and Q&A
Signum close
Dan Leffler, Boston, United States
Summary and close
Christophe Cellier, Paris, France
Diagnosis and treatment of refractory celiac disease
Christophe Cellier, Paris, France
Diagnosis and treatment of non-responsive celiac disease
Chris Mulder, Amsterdam, Netherlands
Non-celiac disease associated enteropathies and lymphomas
Joseph Murray, Rochester, United States
New classification of T intestinal cell lymphoma and targeted treatments
Olivier Hermine, Paris, France
Non-responsive and Refractory Coeliac Disease: The Largest UK Experience from the NHS England Rare Diseases Collaborative Network
Hugo Penny, Sheffield, United Kingdom
Characterization of a large cohort of children with non-celiac auto-immune enteropathies
Fabienne Charbit-Henriton, Paris, France

Imagining the future: how will the celiac disease patient journey change over the next 10 years?

Keynote Lecture: The interplay between genetics and environment in type 1 diabetes
Chairpersons: Daniel Agardh, Lund, Sweden; Mikael Knip, Helsinki, Finland

Epidemiology & environmental triggers
Chairpersons: Daniel Agardh, Lund, Sweden; Elena Verdu, Ontario, Canada

Natural history of celiac disease: lessons from at risk pediatric cohorts
Daniel Agardh, Lund, Sweden

Mechanistic insight into the role of microbiota in intestinal inflammation
Harry Sokol, Paris, France

Environmental factors: update on the role of gut microbiota in celiac disease
Elena Verdu, Ontario, Canada

Metagenomic analysis of fecal virome identifies specific enteroviruses and adenoviruses as potential triggers of celiac disease autoimmunity in the TEDDY study
Kati Lindfors, Tampere, Finland

Gluten intake and risk of celiac disease
Carin Andreon Aronsson, Malmo, Sweden
### FRIDAY, SEPTEMBER 6TH, 2019

#### CLINICAL FORUM - ROOM FORUM – LEVEL -1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 08:00 - 09:15 am | **Difficult diagnosis**  
Chairpersons: Julio Bai, Buenos Aires, Argentina; Julie Bruneau, Paris, France |
| 08:00 - 08:15 am | A patient with positive serology and normal duodenal biopsy  
Govind Mahkaria, New Delhi, India |
| 08:15 - 08:30 am | Histological uncertainties including patients with IEL only on duodenal biopsy  
Umberto Volta, Bologna, Italy |
| 08:30 - 08:45 am | Difficult histological diagnosis: RCD or lymphoma?  
Julie Bruneau, Paris, France |
| 08:45 - 09:00 am | What to do in a patient already on a GFD?  
Julio Bai, Buenos Aires, Argentina |
| 09:00 - 09:15 am | Villous atrophy and negative serology or negative HLADQ2/8  
Carolina Ciacci, Salerno, Italy |
| 09:15 - 10:30 am | **Symposium sponsored by Dr. Schär** |
| 09:15 - 09:25 am | **Differential diagnose in GRD: keys of a good patient management**  
David Sanders, Sheffield, United Kingdom |
| 09:25 - 09:40 am | A GFD is not equal to a GFD: Quality of the diet for quality of life  
Nick Trott, Sheffield, United Kingdom |
| 09:40 - 09:55 am | Follow up of the patient: which balance for the best compliance?  
Benjamin Lebwohl, New-York, United States |
| 09:55 - 10:05 am | Nutritional profiles compared: processed GF food and their gluten containing equivalents (or counterparts)  
Paula Crespo Valladolid, Spain |
| 10:05 - 10:15 am | Re-Cereal: an innovative project to improve products’ quality  
Veronica Marín, Trieste, Italy |
| 10:15 - 10:30 am | Questions & Answers |
| 10:00 - 10:30 am | **Coffee break** |
| 10:45 - 12:05 pm | **The gluten free diet beyond the gut**  
Chairpersons: Joseph Murray, Rochester, United States; Carolina Ciacci, Salerno, Italy |
| 10:45 - 11:00 am | State-of-the-art lecture: the gluten free diet: safe or dangerous?  
Benjamin Lebwohl, New-York, United States |
| 11:10 - 11:25 am | Are there nutritional consequences of a gluten free diet?  
Nick Trott, Sheffield, United Kingdom |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:25 - 11:40 am | **The gluten free diet in neurological disease**  
Marios Hadjivassiliou, Sheffield, United Kingdom |
| 11:40 - 12:05 pm | State-of-the-art lecture: assessing adherence many questions no answers?  
Julio Bai, Buenos Aires, Argentina |
| 12:10 - 01:45 pm | **Lunch & poster session** |
| 01:45 - 03:00 pm | **Non-celiac gluten sensitivity & IBS and IBD**  
Chairpersons: Knut E A Lundin, Oslo, Norway; Umberto Volta, Bologna, Italy |
| 01:45 - 02:05 pm | State-of-the-art lecture: how the microbiome will change our practice?  
Harry Sokol, Paris, France |
| 02:05 - 02:25 pm | Update on pathogenesis of NCGS  
Knut E A Lundin, Oslo, Norway |
| 02:25 - 02:45 pm | IBS GFD and FODMAPs  
Sherine Khater, Paris, France |
| 02:45 - 03:00 pm | NGCS, celiac disease and IBS: how to differentiate?  
Umberto Volta, Bologna, Italy |
| 03:00 - 03:45 pm | **Coffee break** |
| 03:45 - 05:00 pm | **New developments in celiac disease**  
Chairpersons: Dan Leffler, Boston, United States; Maria Luisa Maerin, Leiden, Netherlands |
| 03:45 - 04:05 pm | How to organize a celiac disease center?  
Chris Mulder, Amsterdam, Netherlands |
| 04:05 - 04:20 pm | Do adult celiac patients need Vitamin D supplementation?  
Carolina Ciacci, Salerno, Italy |
| 04:20 - 04:40 pm | Prevention of celiac disease: is it possible?  
Riccardo Troncone, Naples, Italy |
| 04:40 - 05:00 pm | Round table: The evolving role of patient advocacy groups  
Heidi Urwin, Buckinghamshire, United Kingdom; Christel Turcat, Paris, France; Tunde Koltai, Brussels, Belgium; Hilary Croft, Bucks, United Kingdom |
| 05:05 - 06:00 pm | **Drink and Posters** |
### SATURDAY, SEPTEMBER 7TH, 2019

**SCIENTIFIC FORUM - ROOM SCENE - LEVEL 0**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chairpersons</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:50 am</td>
<td><strong>Immunotherapy sponsored by ImmusanT</strong></td>
<td>AUDITORIUM - LEVEL-1</td>
<td></td>
<td>Immunotherapy antigen-specific in autoimmune diseases. David Wraith, Birmingham, United Kingdom. Immunotherapy in celiac disease. Bob Anderson, Cambridge, United States.</td>
</tr>
</tbody>
</table>

**18th International Celiac Disease Symposium • WWW.ICDS2019-PARIS.COM**

---

**10:00 - 10:50 am**

- **Immunotherapy sponsored by ImmusanT**
  - Immunotherapy antigen-specific in autoimmune diseases
    - David Wraith, Birmingham, United Kingdom
  - Immunotherapy in celiac disease
    - Bob Anderson, Cambridge, United States

**10:50 - 11:15 am**

- **New development in the treatment of celiac disease**
  - New therapies for celiac disease: overview
    - Chaitan Khosla, Stanford, United States
  - Tolerogenic Immune-Modifying Nanoparticles Containing Gliadin Restore Tolerance and Abrogate Disease in Murine Models of Coeliac Disease
    - Tobias Freitag, Helsinki, Finland
  - Absence of clinical symptoms and negative serological tests could not predict gut mucosal recovery in celiac patients. Correlation of gut mucosal damage with the presence of urine gluten peptides
    - Angel Cebolla-Ramirez, Seville, Spain

**11:15 - 11:30 pm**

- **Sum up of the congress**
  - Joseph Murray, Rochester, United States
  - Prizes for posters and oral communication
    - Nadine Cerf-Bensussan, Paris, France
    - Chrisophe Cellier, Paris, France

---

**12:15 - 12:30 pm**

- **Prizes for posters and oral communication**
  - Nadine Cerf-Bensussan, Paris, France
  - Chrisophe Cellier, Paris, France

---

**08:30 - 09:30 am**

- Update on larazotide acetate: Currently in 1st ever P3 trial for celiac disease
  - Steve Laumas, New-York, United States
Visit our website for information on our celiac disease program and pipeline: 

www.innovatebiopharma.com

Innovate wishes the delegates of the 18th International Celiac Disease Symposium a successful conference
# POSTER SESSIONS

## DIAGNOSIS

**TOUR 1: THURSDAY, SEPTEMBER 5TH FROM 12:30 PM TO 01:30 PM**

**POSTER TOUR LEADERS:**
- Sherine Khater, Paris, France
- Julie Bruneau, Paris, France
- Eleni Lionetti, Ancona, Italy
- Prasenjit Das, New Delhi, India
- Maxine Dominique Rouvroye, Amsterdam, Netherlands

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-01</td>
<td>Is it a biased association? Review of the co-prevalence of eosinophilic esophagitis and celiac disease.</td>
<td>Jennifer Hong, Baltimore, United States</td>
</tr>
<tr>
<td>P1-02</td>
<td>Don't jump into the Marsh: Awareness of Celiac Disease overdiagnosis in adult community practices</td>
<td>Runa Watkins, Baltimore, United States</td>
</tr>
<tr>
<td>P1-03</td>
<td>Blood AND Guts? - Improving the Diagnostic Accuracy for Celiac Disease</td>
<td>Richard Charlesworth, Armidale, Australia</td>
</tr>
<tr>
<td>P1-04</td>
<td>The Predictive Value of Serum Cytokines for Distinguishing Celiac Disease from non-celiac gluten sensitivity and healthy subjects</td>
<td>Mohammad Rostaminejad, Tehran, Iran</td>
</tr>
<tr>
<td>P1-05</td>
<td>Intestinal transglutaminase 3 and transglutaminase 2-specific plasma cell responses in dermatitis herpetiformis patients undergoing a gluten challenge</td>
<td>Minna Hietikko, Tampere, Finland</td>
</tr>
<tr>
<td>P1-06</td>
<td>Intestinal transglutaminase 3 and transglutaminase 2-specific plasma cell responses in dermatitis herpetiformis patients undergoing a gluten challenge</td>
<td>Katri Lindfors, Tampere, Finland</td>
</tr>
<tr>
<td>P1-07</td>
<td>Inter and Intra-assay variation in the diagnostic performance of anti-tissue transglutaminase antibody assays in two ethnic populations</td>
<td>Govind Makharia, New Delhi, India</td>
</tr>
<tr>
<td>P1-08</td>
<td>Automated Analyzers are Suited for Diagnosing Celiac Disease Following the ESPGHAN 2012 Criteria</td>
<td>Raanam Shamir, Petach Tikva, Israel</td>
</tr>
<tr>
<td>P1-09</td>
<td>Diagnostic Yield of Small Bowel Ultrasonography compared to Video Capsule Endoscopy for the diagnosis of complicated Celiac Disease</td>
<td>Andrea Costantino, Milano, Italy</td>
</tr>
<tr>
<td>P1-10</td>
<td>The impact of clinical presentation of celiac disease on diagnostic delays in children in Central Europe</td>
<td>Petra Riznik, Maribor, Slovenia</td>
</tr>
<tr>
<td>P1-11</td>
<td>The influence of diagnostic delays on growth of children with celiac disease in Central Europe</td>
<td>Petra Riznik, Maribor, Slovenia</td>
</tr>
<tr>
<td>P1-12</td>
<td>Positive Celiac Disease serology in risk groups: a diagnostic challenge.</td>
<td>Ester Donat, Valencia, Spain</td>
</tr>
<tr>
<td>P1-13</td>
<td>The occurrence of gluten associated antibodies and the level of I-FABP in adult patients with diarrhea-predominant irritable bowel syndrome</td>
<td>Joanna Bierla, Warsaw, Poland</td>
</tr>
<tr>
<td>P1-14</td>
<td>Nutritional quality of a gluten-free diet at low content of FODMAP in patients with Celiac Disease</td>
<td>Alice Scricciolo, Milano, Italy</td>
</tr>
<tr>
<td>P1-15</td>
<td>Overlooked Celiac Crisis in Children in the World of Changing Clinical Patterns</td>
<td>Cristina Ungureanu, Bucharest, Romania</td>
</tr>
<tr>
<td>P1-16</td>
<td>Gladin Specific Peripheral T Cell Response In Dermatitis Herpetiformis Patients Undergoing A Gluten Challenge: A Biomarker For Predicting Clinical Relapse?</td>
<td>Esko Kemppainen, Tampere, Finland</td>
</tr>
<tr>
<td>P1-17</td>
<td>Celiac Disease in Patients with Cirrhosis and Hypertramsaminasemia: A Systematic Review and Meta-analysis</td>
<td>Shakira Yoosuf, Boston, United States</td>
</tr>
<tr>
<td>P1-18</td>
<td>Prevalence and Diagnostic Outcomes of Seronegative Villous Atrophy in Children</td>
<td>Marleena Repo, Tampere, Finland</td>
</tr>
<tr>
<td>P1-19</td>
<td>Assessment of celiac disease severity by video capsule endoscopy with the celiac enteropathy - villous atrophy scale (CE-VAST)</td>
<td>Jenifer Siegelman, Cambridge, United States</td>
</tr>
<tr>
<td>P1-20</td>
<td>Celiac disease and associated dermatological manifestations: a study of 280 patients</td>
<td>Ferdaouss Lamarti, Rabat, Morocco</td>
</tr>
<tr>
<td>P1-21</td>
<td>Endoscopy to Evaluate Suspected Celiac, is Visual Assessment of Esophagus and Stomach Enough?</td>
<td>Maria Cristina Pacheco, Seattle, United States</td>
</tr>
<tr>
<td>P1-22</td>
<td>The Utility of IgA Based Serologic Markers in Diagnosing Celiac Disease in Children ≥24 Months of Age</td>
<td>Imad Absah, Rochester, United States</td>
</tr>
<tr>
<td>P1-23</td>
<td>Celiac disease and reproductive disorders: correlation and evolution under gluten-free diet</td>
<td>Manal Mahmoudi, Rabat, Morocco</td>
</tr>
<tr>
<td>P1-24</td>
<td>Is celiac disease a cause of venous thrombosis? Experience of a Moroccan university department.</td>
<td>Soukaina Zertiti, Rabat, Morocco</td>
</tr>
<tr>
<td>P1-25</td>
<td>Significance of the severity of diagnostic lesion in pediatric celiac disease: do we need the biopsy for prognostic reasons?</td>
<td>Sofia Kröger, Tampere, Finland</td>
</tr>
<tr>
<td>P1-26</td>
<td>Dermatitis Herpetiformis in Childhood and Linking Dermopathy to Enteropathy</td>
<td>Arunjot Singh, Philadelphia, United States</td>
</tr>
<tr>
<td>P1-27</td>
<td>Is there any correlation between serology and histology in celiac disease?</td>
<td>Manal Mahmoudi, Rabat, Morocco</td>
</tr>
<tr>
<td>P1-28</td>
<td>Comparison between axial and lateral/panoramic view capsule endoscopy in patients with celiac disease: results from a prospective randomized study</td>
<td>Luca Ell, Milano, Italy</td>
</tr>
<tr>
<td>P1-29</td>
<td>Compliance With Guideline Recommended Biography Protocol In Consecutive Incident Cases Of Celiac Disease: A Retrospective Study From A Tertiary Care Institution</td>
<td>William Kessler, Indianapolis, United States</td>
</tr>
<tr>
<td>P1-30</td>
<td>High prevalence of irritable bowel syndrome diagnosis in patients referred to Adult Celiac Disease Clinic - Lack of knowledge of differential diagnosis or insufficient recognition of guidelines?</td>
<td>Silvija Cukovic-Cavka, Zagreb, Croatia</td>
</tr>
</tbody>
</table>
**POSTER SESSIONS**

**P1-35** Comparative performance of commercial diagnostic antibody tests in celiac disease patients with and without intestinal abnormalities
Daan Castelijn, Amsterdam, Netherlands

**P1-36** The impact of gluten challenge with different doses of gluten in patients with irritable bowel syndrome
Mohammad Rostami-Nejad, Tehran, Iran

**P1-37** How low FODMAP gluten free diet affect the anxiety level in patients with irritable bowel syndrome?
Mohsen Norouzinia, Tehran, Iran

**P1-38** Neurocognitive and Behavioral Functioning Following Initiation of a Gluten Free Diet in Children with Celiac Disease
Lesley Small-Harary, Stony Brook, United States

**P1-39** Neurocognitive effects of gluten exposure: Qualitative results of a nationwide survey
Alice Bast, Ambler, United States

**P1-40** CELIAC RELATED HEPATITIS - do we recognize the problem?
Ivana Knezevic Stromar, Zagreb, Croatia

**P1-41** A Case for Early Diagnosis of Celiac Disease & its Potential to Prevent Co-Existing Autoimmune Conditions
Patricia Bieryl, Philadelphia, United States

**P1-42** Titanium modified electrodes for gluten detection in food
Cristina Dumitriu, Bucharest, Roumania

**P1-43** Celiac disease patients have lower sence of coherence score than healthy controls
Efrat Broide, Zerifin, Israel

**P1-44** ESPGHAN Guidelines for Diagnosis of Celiac Disease 2019
Steffen Husby, Odense C, Germany

**P1-45** MED ABOUT DATA HACKATHON – Making Early Diagnosis of Celiac Disease Possible
Liat Kosovitch, Haifa, Israel

**P1-46** Assessment of new biomarkers for diagnosis and monitoring of celiac disease
Erika Monguzzi, Mainz, Germany

**P1-47** Global consensus on definition and histological classification of non-celiac gluten sensitivity.
Kamran Rostami, Palmerston North, New Zealand

**P1-48** The use of biopsy and “no-biopsy” approach for diagnosing paediatric celiac disease in the Central European region
Petra Rizniki, Maribor, Slovenia

**P1-49** Appropriate Screening for Celiac Disease at a Children’s Hospital Results in Increased Testing and Decreased Charges
Michael Bates, Dayton, United States

**P1-50** Time trends of the clinical presentation and diagnosis of celiac disease
Thora Marie Hoegh-Andersen, Odense, Denmark

**P1-51** Positive Predictive Value of the new generation celiac rapid test, for screening in healthy school children.
Manoubia Bensmina, Algiers, Algeria

---

**EPIDEMIOLOGY/DIAGNOSTIC**

**P2-01** Long-term consequences of undiagnosed celiac disease
Line Lund Kårhus, Copenhagen, Denmark

**P2-02** No Association Between HLA-DQA1*05 and -DQB1*02 Gene Dosage and Clinical Phenotype of Celiac Disease
Hugo Penny, Sheffield, United Kingdom

**P2-03** Should we be Diagnosing Celiac Disease in the Elderly?
Hugo Penny, Sheffield, United Kingdom

**P2-04** High Rates of Testing for Celiac Disease Serology, and Low Rates of Endoscopy in a Large Real-World Database
Raanan Shamir, Petach Tikva, Israel

**P2-05** Overall and Cause-Specific Mortality in Adult Celiac Disease: Population-Based Study in Contemporary Era
Inka Koskinen, Tampere, Finland

**P2-06** Patient burden and treatment experience in celiac disease
Daniel A. Leffler, Cambridge, United States

**P2-07** Immunogenetic polymorphisms in celiac disease in patients from Morocco
Soukaina Zertiti, Rabat, Morocco

**P2-08** Understanding celiac disease outcomes and monitoring patterns after diagnosis: a multinational study
Daniel A. Leffler, Boston, United States

**P2-09** Assessing severity and healthcare resource utilization in celiac disease: a U.S. claims data analysis
Daniel A. Leffler, Boston, United States

**P2-10** Undiagnosed celiac disease in women with recurrent reproductive failure
Concepción Núñez, Madrid, Spain

**P2-11** Economic burden of celiac disease in the U.S.
Song Wang, Cambridge, United States

**P2-12** Adherence to the gluten-free diet and patient outcomes: Real world evidences from an international patient registry, iCureCeliac
Kristina Chen, Cambridge, United States

**P2-13** The knowledge of medical professions on celiac disease in opinion of Polish patients with celiac disease
Emilia Majsiak, Lublin, Poland

**P2-14** The frequency of testing and diagnosing with CD family members of Polish patients with confirmed CD
Emilia Majsiak, Lublin, Poland

---

**POSTER TOUR LEADERS:**

Renata Auricchio, Naples, Italy
Ritu Verma, Chicago, United States
Gerd Bouna, Amsterdam, Netherlands
Paula Crespo, Valladolid, Spain
# POSTER SESSIONS

## P2-17
The changes in manner of diagnosing CD among Polish children
Emilia Majskiak, Lublin, Poland

## P2-18
The bottom of the Celiac Disease (CD) iceberg: a disease still underestimated in Rome
Italo De Vitis, Roma, Italy

## P2-19
Distribution of HLA-DQ2 and HLA-DQ8 alleles in native South Indian population
Anil Verma, Ancona, Italy

## P2-20
Adult celiac disease patients diagnosed in early childhood have less comorbidities but poorer self-perceived health than those diagnosed later
Sara Koskimaa, Tampere, Finland

## P2-21
Gluten free diet and survival in adult patients with celiac disease: Cohort Study
Ferdaouss Lamarti, Rabat, Morocco

## P2-22
Clinical Spectrum of Celiac Disease in Adults at a Tertiary Care Hospital in Karachi, Pakistan
Verda Arshad, Karachi, Pakistan

## P2-23
Phenotypic and genotypic differences between familial and sporadic celiac disease
Laura Airaksinen, Tampere, Finland

## P2-24
HLA-DQ2 dose effect on clinical picture of celiac disease
Laura Airaksinen, Tampere, Finland

## P2-25
Characterizing the Phenotype of Very Early Onset Celiac Disease
Arunjot Singh, Philadelphia, United States

## P2-26
A sex-based comparison of initial presentation and disease severity in celiac disease
Stephanie Moleski, Philadelphia, United States

## P2-27
Exploring the profile of celiac disease between adult and pediatric celiac patients
Efrat Broide, Zerifin, Israel

## P2-28
Infantile Onset Celiac Disease is Different from Celiac Disease presenting in older children
Sadhna Bhasin Lal, Chandigarh, India

## P2-29
Spectrum Of Presentation in children with Celiac Disease in the Celiac Belt Of India
Sadhna Bhasin Lal, Chandigarh, India

## P2-30
Correlation Between Total IgA and Tissue Transglutaminase IgA antibodies
Stine Dydensborg Sander, Odense, Denmark

## P2-31
Prevalence of celiac disease among school-aged children in Algiers
Manoubia Bensmina, Algiers, Algeria

## P2-32
Co-occurrence of Celiac Disease and Type 1 Diabetes in diverse ethnic groups at the University of Chicago
Valentina Discepolo, Chicago, United States

## EPIDEMIOLOGY/ENVIRONMENTAL TRIGGERS

### TOUR 2: THURSDAY, SEPTEMBER 5TH FROM 05:00 PM TO 06:00 PM

#### POSTER TOUR LEADERS:
Carin Andrén Aronsson, Malmo, Sweden
Valerie Byrnes, Boston, United States

<table>
<thead>
<tr>
<th>P3-01</th>
<th>Symptoms, Gluten Free Diet (GFD) Adherence, and Laboratory Data Do Not Predict Duodenal Mucosal Healing in Celiac Disease (CeD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Marie Robert, New Haven, United States</td>
</tr>
<tr>
<td>P3-02</td>
<td>Anxiety in treated adult celiac patients and the effect of duration of gluten-free diet on its improvement</td>
</tr>
<tr>
<td></td>
<td>Mohammad Rostami-Nejad, Tehran, Iran</td>
</tr>
<tr>
<td>P3-03</td>
<td>Screening for celiac disease in Tunisian patients with chronic hepatitis C</td>
</tr>
<tr>
<td></td>
<td>Syrine Safar, Sousse, Tunisia</td>
</tr>
<tr>
<td>P3-04</td>
<td>Development of a Sequence Searchable Celiac Database of Peptides and Proteins for Risk Assessment of Novel Food Proteins</td>
</tr>
<tr>
<td></td>
<td>Richard E Goodman, Lincoln, United States</td>
</tr>
<tr>
<td>P3-05</td>
<td>Mice colonized with duodenal microbiota of DR3-DQ2 positive individuals without celiac disease exhibit effective gluten metabolic capacity</td>
</tr>
<tr>
<td></td>
<td>Alberto Caminero, Hamilton, Canada</td>
</tr>
<tr>
<td>P3-06</td>
<td>First-degree relatives of celiac disease patients have increased seroreactivity to serum microbial markers</td>
</tr>
<tr>
<td></td>
<td>Liisa Viitasalo, Tampere, Finland</td>
</tr>
<tr>
<td>P3-07</td>
<td>Prospective Longitudinal Gut Metagenomic Analysis Suggests An Altered Microbiome Composition and Function in Infants Prior to Celiac Disease Onset</td>
</tr>
<tr>
<td></td>
<td>Maureen M Leonard, Boston, United States</td>
</tr>
<tr>
<td>P3-08</td>
<td>Link between patients with likely celiac disease and positive serology for Lyme disease</td>
</tr>
<tr>
<td></td>
<td>F. Ramzi Asfour, San Rafael, United States</td>
</tr>
<tr>
<td>P3-09</td>
<td>Comparison of R5 and G12 antibody-based ELISA methods for the determination of gluten concentration in routine gluten-free food products</td>
</tr>
<tr>
<td></td>
<td>Anil Verma, Ancona, Italy</td>
</tr>
<tr>
<td>P3-10</td>
<td>Season of birth and early life events on the risk of celiac disease in genetically at-risk children: TEDDY study</td>
</tr>
<tr>
<td></td>
<td>Anna Laitinen, Tampere, Finland</td>
</tr>
<tr>
<td>P3-11</td>
<td>Probiotics: If it does not help it does not do any harm in celiac disease. Really?</td>
</tr>
<tr>
<td></td>
<td>Aaron Lerner, Wendelsheim, Germany</td>
</tr>
<tr>
<td>P3-12</td>
<td>Microbial Transglutaminase is Beneficial to Food Industries but a Caveat to Public Health</td>
</tr>
<tr>
<td></td>
<td>Aaron Lerner, Wendelsheim, Germany</td>
</tr>
<tr>
<td>P3-13</td>
<td>Gluten content estimation in unlabeled and labeled gluten-free food products and commonly used food items consumed by celiac disease patients</td>
</tr>
<tr>
<td></td>
<td>Wajiha Mehtab, Delhi, India</td>
</tr>
<tr>
<td>P3-14</td>
<td>Comparison of early life exposure to enterovirus between children who later developed celiac disease and healthy controls</td>
</tr>
<tr>
<td></td>
<td>Kärt Simre, Tartu, Estonia</td>
</tr>
</tbody>
</table>
POSTER SESSIONS

**P3-16** Comparison of cost and nutritional composition of gluten-free food with their gluten containing counterparts  
Wajiha Mehtab, Delhi, India

**P3-17** Do Canadian adults following a gluten-free diet need supplements to meet their nutritional requirements?  
Richa Chibbar, Boston, United States

**P3-18** Celiac disease and inflammatory bowel disease in patients with IgA nephropathy over time  
Marleena Repo, Tampere, Finland

**P3-19** The Intestinal Microbiome in Pediatric Celiac Disease Patients: before diagnosis and one year later in relationship to symptoms and anti-tissue transglutaminase (aTG) serology  
Dory Sample, Edmonton, Canada

**P3-20** Determination of gluten traces in the daily gluten-free diet of children with celiac disease: a quantitative analysis.  
Elena Lionetti, Ancona, Italy

**P3-21** Gluten free Vs Gluten-containing bread lipid profile and sodium content: results from a comparative market study  
Anna Gibert, Barcelona, Spain

**P3-22** Prospective study of smoking in pregnancy and risk of celiac disease in offspring  
Karl Marild, Gothenburg, Norway

**P3-23** Has gluten recently changed in composition or processing?  
Katharina Scherf, Freising, Germany

**P3-24** Parechovirus infections and increased risk of celiac disease: nested case-control study within the MIDIA longitudinal birth cohort  
Ketil Størdal, Oslo, Norway

**P3-25** Cord blood metabolites and risk of coeliac disease in childhood  
Ketil Størdal, Oslo, Norway

**P3-26** Serum antibodies to Type 1 Lang reovirus, but not enterovirus or rotavirus, are increased in children with celiac disease  
Michael Fitzpatrick, Oxford, United Kingdom

**P3-27** Characterization of Amylase trypsin inhibitors from different wheat species  
Massimiliano Cucchiolini, Camerino, Italy

**P3-28** Celiac Disease Adherence Test does not detect short term dietary adherence to gluten-free diet  
Wajiha Mehtab, Delhi, India

**P3-29** Wheat amylase trypsin inhibitors (ATI) negatively affect intestinal microbiota and aggravate experimental colitis  
Johannes Matzner, Mainz, Germany

**P3-30** Impact of germination on gluten, amylase inhibition and immune stimulatory potential of amylase trypsin inhibitors (ATIs) in different wheats  
Manjusha Neerukonda, Mainz, Germany

**P3-31** Wheat amylase trypsin inhibitors (ATI) promote liver fibrosis in a murine model of biliary fibrosis  
Muhammad Ashfaq-Khan, Mainz, Germany

**P3-32** Nutritional wheat amylase trypsin inhibitors (ATI) promote murine non-alcoholic steatohepatitis and the metabolic syndrome  
Muhammad Ashfaq-Khan, Mainz, Germany

**P3-33** Use of micro-CT imaging of intestinal biopsies to improve the diagnostics of celiac disease  
Johannes Virta, Tampere, Finland

**P3-34** Celiac Dietary Adherence Test simplifies determining adherence to gluten-free diet  
Katarina Johansson, Umeå, Sweden

**P4-01** Delusion-Like Beliefs in Celiac Disease: A Qualitative Investigation  
Rose-Marie Satherley, London, United Kingdom

**P4-02** Assessing Gluten Free Diet Adherence using CDAT and Biagi Questionnaires in Patients with Celiac Disease  
Hugo A Penny, Sheffield, United Kingdom

**P4-03** A Quantitative Analysis of Gluten Contamination in Everyday School Supplies and Concern for Children with Celiac Disease  
Vanessa Weisbrot, Washington D.C., United States

**P4-04** Associations between executive skills and daily activities while maintaining a gluten free diet  
Sonya Meyer, Haifa, Israel

**P4-05** A Family Affair: The Impact of Managing a Child’s Celiac Disease on Caregivers  
Mary Shull, Aurora, United States

**P4-06** Daily life decision making in pediatric celiac disease: What are the decisions and who makes them?  
Sonya Meyer, Haifa, Israel

**P4-07** Prescribing gluten-free foods: the impact of policy changes on quality of life  
Helen Crocker, Oxford, United Kingdom

**P4-08** Guidelines to determine Follow-up Intervals for Celiac Disease based on data mining techniques  
Alfonso Rodríguez-Herrera, Kilbenny, Spain

**P4-09** Utility of Symptom Severity, Frequency, and Lability in Predicting Serology Status And Villous Injury in Adults with Treated Celiac Disease  
Adam Bledsoe, Rochester, United States

**P4-10** A score to identify celiac patients who need a follow-up biopsy  
Anna Gibert, Barcelona, Spain
## POSTER SESSIONS

| P4-14 | Perceived Psychosocial Distress Improves in Youth and their Parents after Diagnosis of Celiac Disease  
Shayna Coburn, Washington D.C., United States |
| P4-15 | Psychological Needs and Services in a Multidisciplinary Celiac Disease Clinic  
Shayna Coburn, Washington D.C., United States |
| P4-16 | Occasional ingestions of gluten are tolerated in a group of patients with celiac disease  
Luca Elli, Milano, Italy |
| P4-17 | Development and technical validation of tetramer staining for use as biomarker for assessing gluten-specific T cells in clinical studies  
Glenda M. Smithson, Cambridge, United States |
| P4-18 | A telephone clinic improves gluten-free dietary adherence in adults with celiac disease  
Yvonne Jeanes, London, United Kingdom |
| P4-19 | Novel Celiac Disease Program Model Improves Follow-Up Adherence  
Angie Almond, Winston-Salem, United States |
| P4-20 | Celiac Disease and the Family: A Mixed Methods Systematic Review  
Rose-Marie Satherley, London, United Kingdom |
| P4-21 | Coexisting type 1 diabetes increases the risk of dietary lapses in adult celiac disease patients diagnosed in childhood  
Laura Kivelä, Tampere, Finland |
| P4-22 | Patients with celiac disease are at high risk of metabolic syndrome and fatty liver  
Govind Makharia, New Delhi, India |
| P4-23 | Assessment of Knowledge of Gluten-Free Diet Amongst Food Handlers in a Health Care Institution  
Tyler Mullen, Halifax, Canada |
| P4-24 | The role of low FODMAP plus gluten free diet on the quality of life of irritable bowel syndrome patients  
Mohammad Rostami-Nejad, Tehran, Iran |
| P4-25 | The awareness of health care professionals for diagnosis and treatment of celiac disease compared with celiac patients  
Faroukh Barzegar, Tehran, Iran |
| P4-26 | The Milano questionnaire: a new dietary score for evaluation of compliance to gluten free diet in patients with celiac disease  
Luca Elli, Milano, Italy |
| P4-27 | High prevalence of persisting symptoms, fatigue and reduced quality of life among treated adult celiac patients in a national cross-sectional study  
Frida Van Megen, Oslo, Norway |
| P4-28 | Factors associated with non adherence to gluten free diet in adults celiac patients in Israel  
Dana Zelnik Yovel, Zerifine, Israel |
| P4-29 | Gall Bladder Dysfunction In children With Celiac Disease  
Sadhna Bhasin Lal, Chandigarh, India |
| P4-30 | Gluten-Free Global Threshold Wars - How Safe is Safe?  
Paul Valder, Toronto, Canada |
| P4-31 | High Rates of Depression in Adolescent Celiac Patients  
Ritu Verma, Chicago, United States |
| P4-32 | A Real-Life Assessment of Gluten Cross-Contact In A Shared Kitchen Environment  
Vanessa Weisbord, Washington D.C., United States |
| P4-33 | A qualitative exploration of what people living with celiac disease think about their long-term follow up care  
Rosie Cooper, Derby, United Kingdom |
| P4-34 | Healthcare Professionals’ Views On The Long-term Follow Up Of Celiac Disease: A Qualitative Study  
Rosie Cooper, Derby, United Kingdom |
| P4-35 | Different mineral and vitamin content in gluten free products comparing to gluten-containing counterparts  
Idoia Larretxi, Vitoria, Spain |
| P4-36 | Tools for nutritional education in the field of gluten-free diet  
Idoia Larretxi, Vitoria, Spain |
| P4-37 | FODMAP consumption among celiac people and its relationship with the gastrointestinal symptomatology  
Idoia Larretxi, Vitoria, Spain |
| P4-38 | Serum IgA anti-tissue transglutaminase antibody trend of normalization in response to the gluten-free diet at short-term follow-up evaluations  
Chiara Monachesi, Ancona, Italy |
| P5-01 | Relative rates of gluten digestion by nine commercial dietary digestive supplements  
Gregory Tanner, Elwood, Australia |
| P5-02 | Concordance of Bulb and Distal Duodenum in Celiac Disease Follow Up Biopsies: Limited Clinical Relevance of Bulb Only Persistent Mucosal Injury  
Marie Robert, New Haven, United States |
| P5-03 | Utility of PAXgene molecular fixative for tissue-based histological, immunohistochemical and RNA gene expression assays of duodenal biopsies in celiac disease  
Juha Taavela, Jyväskylä, Finland |
| P5-04 | Assessing Gluten Free Diet Adherence using Gluten Immunogenic Peptides in the urine of patients with Celiac Disease: First UK Pilot Study  
Hugo A Penny, Sheffield, United Kingdom |
| P5-05 | Towards predictive circulating biomarkers for celiac disease - a next-generation sequencing microRNA transcriptomics approach  
Ineke Tan, Groningen, Netherlands |
**POSTER SESSIONS**

**P5-06**
Establishing kit-independent calibrators for measuring serum transglutaminase 2 antibody concentrations for the prediction of celiac disease
Rita Elek, Debrecen, Hungary

**P5-07**
Use of Enteric-Release Budesonide in Non-Responsive Celiac Disease
Amelie Therrien, Boston, United States

**P5-08**
Investigation of binding properties and kinetics of antibodies against deamidated gliadin peptides from celiac and non-celiac subjects
Adám Diós, Debrecen, Hungary

**P5-09**
Analysis of faecal Gluten Immunogenic Peptides to determine gluten intake during the diagnosis of celiac disease and in the transition to a gluten-free diet
Remedios Domínguez, Sevilla, Spain

**P5-10**
Stratification of a Large Cohort of Hungarian Celiac Patients at Diagnosis and Follow-up by a New Particle-Based Multi-Analyte Assay
Gary Norman, San Diego, United States

**P5-11**
Quantitative Histology-Based Classification System for Assessment of the Intestinal Mucosal Histological changes in Patients with Celiac Disease
Prasenjit Das, New Delhi, India

**P5-12**
I-FABP - serological biomarker of an impaired epithelial barrier in children with type 1 diabetes mellitus and celiac disease
Bozena Cukrowska, Warsaw, Poland

**P5-13**
Endopeptidase-40 (E40), a novel glutenase from the actinomycete Actinoallomurus strain A8
Linda Cavaletti, Gerenzano, Italy

**P5-14**
The microbial endopeptidase-40 (E40) efficiently neutralizes the T cell stimulatory activity of gluten proteins
Carmen Gianfrani, Naples, Italy

**P5-15**
Analysis of gluten immunogenic peptides in faeces to assess adherence to the gluten free diet in celiac patients.
Ester Donat, Valencia, Spain

**P5-16**
Epicutaneous Immunotherapy Suppresses Gluten Dependent Inflammation In A Mouse Model Of Celiac Disease
Eric Marietta, Rochester, United States

**P5-17**
Efficacy Of Pancreatic Enzyme Supplementation For Symptom Control In Non-Responsive Celiac Disease Patients
Caitlin Barrett, Boston, United States

**P5-20**
Real life patterns of dietary transgressions in long-term gluten-free diet treated celiac patients by using GIP excretion
Sonia Niveloni, Buenos Aires, Argentina

**P5-21**
Celiac Facts – Online-Courses for Health Care Professionals and Patients
Katharina Julia Werkstetter, Munich, Germany

**P5-22**
Bifidobacterium infantis NSL Super Strain in highly symptomatic celiac disease patients on long-term gluten-free diet. A pilot study
Sonia Niveloni, Buenos Aires, Argentina

**P5-23**
AGY for Patients with Symptomatic Celiac Disease: Protocol for a Randomized, Placebo-controlled Phase II Trial
Dory Sample, Edmonton, Canada

**P5-24**
CD38 expression on gluten-specific CD4+ T cells is a sensitive biomarker for gluten exposure in celiac disease patients on a gluten-free diet
Louise Fremgaard Risnes, Oslo, Norway

**P5-25**
A novel artificial intelligence based approach to the diagnosis of celiac disease, based on T-cell receptor repertoires
Elizabeth Soilleux, Cambridge, United Kingdom

**P5-26**
The enzyme activity of normal structure of small intestinal mucosa in adult celiac disease patients, followed gluten-free diet
Svetlana Bykova, Moscow, Russia

**P5-27**
Tissue Transglutaminase Immunoglobulin A versus Duodenal Mucosal Biopsies—How to Best Assess Duodenal Healing in Pediatric Celiac Disease and Eosinophilic Esophagitis
Lisa Fahey, Philadelphia, United States

**P5-29**
Milk protein-induced villous atrophy and elevated serologies in four children with celiac disease on a gluten-free diet
Ritu Verma, Chicago, United States

**P5-30**
Predictors for mucosal recovery in children with Celiac Disease: iTG is not the answer
Sadhna B Lal, Chandigarh, India

**P5-31**
Lati-glutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet
Jack Syage, Newport Beach, United States

**P5-32**
Minimally-invasive Method for Monitoring Intestinal Villous Health in Recovering Celiac Disease Patients
Jennifer Seale, Durham, United States

**P5-33**
Specific c receptor targeting blocks reprogramming of human tissue-resident cytotoxic lymphocytes by IL-15 and IL-21
Valentina Discepolo, Chicago, United States

**OMICS & PATHOGENESIS**

**P6-01**
Decreased expression of the gluten-degrading lysosomal protease Cathepsin S and the cytokine IL-27 in monocytes of pediatric celiac disease patients
Lea Costes, Rotterdam, Netherlands

**P6-02**
Draft genome of the 33-mer gliadin peptide
Albert Garcia-Quintanilla, Seville, Spain

**P6-03**
Delineating Causal SNPs in Celiac Disease Using SuRE-SNP
Roeland Broekema, Groningen, Netherlands

**P6-04**
New Biophysical and Molecular Approach to Understand Gluten-related Disorders
Veronica Dodero, Belelief, Germany

**P6-05**
The influence of food processing on the release profile of celiac immunogenic peptides from food matrices
Olivia Ogilvie, Auckland, New Zealand
POSTER SESSIONS

P6-06 Celiac disease-on-chip: Modeling a multifactorial disease in vitro
Renée Moerkens, Groningen, Netherlands

P6-07 Functional Study of Genes and Long Non-coding RNAs Associated with Celiac Disease with A Cell-type Specific CRISPR/Cas9 Pooled Screen
Chan Li, Groningen, Netherlands

P6-08 Comparative analysis of capability to activate a pathogenic gluten-specific T cell response by HLA DR6/DR7 and DR3/DR1 positive antigen presenting cells
Giovanna Del Pozzo, Naples, Italy

P6-09 Constitutive alterations in vesicular trafficking increase the sensitivity of cells from celiac disease patients to gliadin
Maria Vittoria Barone, Naples, Italy

P6-10 T cell receptor (TCR) clonotyping in blood and duodenal mucosa: a potential clinical biomarker of gluten response in celiac patients
Glenda M. Smithson, Cambridge, United States

P6-11 The intestinal expansion of TCR+ T cells and the disappearance of IL4+ T cells characterizes the transition from potential to overt celiac disease
Carmen Gianfrani, Naples, Italy

P6-12 Increased density of TCR+ intraepithelial lymphocytes is present in the duodenal mucosa from celiac patients in all stages of the disease and correlates with the extent of mucosal damage
Mariantonia Maglio, Naples, Italy

P6-13 ATIs from ancient diploid wheat have a reduced ability to activate gut innate immune response
Vera Rotondi Auferro, Avellino, Italy

P6-14 LPP and C1orf106 variants confer a genetic predisposition for epithelial barrier dysfunction in celiac disease
Danielle Cardoso Da Silva, Berlin, Germany

P6-15 Molecular histomorphometry as a tool to assess intestinal injury and functional screen on epithelial factors transmitting the injury in celiac disease
Valeria Dotsenko, Tampere, Finland

P6-16 Aerobic energy production is impaired in small bowel epithelial cells in Celiac Disease
Heidi Kontro, Tampere, Finland

P6-17 Comparative analysis of in vitro digestibility and immunogenicity of gliadin proteins from T. durum and T. monococcum wheat
Gianfranco Mamone, Avellino, Italy

P6-18 Effect of celiac peripheral blood mononuclear cells on intestinal epithelial barrier function
Deborah Delbue, Berlin, Germany

P6-19 Investigating Celiac Disease Onset With Single-Cell RNA Sequencing
Aaron Daniel Ramirez-Sanchez, Groningen, Netherlands

P6-20 Identification of plasma cells as gluten peptide-presenting cells by use of peptide-MHCII-specific antibodies
Lene Hoydahl, Oslo, Norway

P6-21 Epitope mapping of mouse monoclonal 885 antibody recognizing a celiac-related surface in transglutaminase 2
Dora Caise, Debrecen, Hungary

P6-25 Study of SlgA receptors in the Caco2 intestinal epithelial cell line
Roman Goguier-Descoumes, Paris, France

P6-26 The Celiac Disease Northern Netherlands cohort (CeDNN): Setting up a biobank allowing multi-omics analyses
Astrid Maatman, Groningen, Netherlands

P6-27 Mechanisms of human SlgA binding to human intestinal epithelial cells
Benoit Clement, Paris, France

P6-28 Cytotoxic effects lead the onset of the gliadin-specific enteropathy in HLA-DQ8 tg mice.
Vera Rotondi Auferro, Avellino, Italy

P6-29 Further Development of a Novel in vivo Model for Celiac Disease in Mice with a Humanized Immune System
Manuel Encalada Ventura, Mainz, Germany

P6-30 Amylase Trypsin Inhibitors (ATIs): Analyses of their bioactivity and protein content in a large spectrum of wheat genotypes cultivated at 3 different locations
Valentina Curella, Mainz, Germany

P6-31 The microbiome in celiac disease: toward studying patient-specific host-microbe interactions
Jelle Slager, Groningen, Netherlands

P6-32 Clustering based approach for population level identification of Celiac disease associated T-cell receptor -chain CDR3 sequences
Päivi Saavalainen, Helsinki, Finland

P6-33 Prediction of potential celiac disease related adverse immune reactions to novel proteins in food
Antonio Fernandez Dumont, Parma, Spain

P6-34 Evaluation Of Intestinal Damage After Gluten Introduction And Prior To Serocversion In Children Developing Celiac Disease Later In Life Data From The PreventCD Cohort
Johanna Kreutz, Maastricht, Netherlands

P6-35 Small intestinal transcriptional analysis outlines celiac disease patients heterogeneity
Valentina Discepolo, Chicago, United States

REFRACTORY CD, NON-CD ENTEROPATHIES & INTESTINAL LYMPHOMAS

TOUR 4: FRIDAY, SEPTEMBER 6TH FROM 05:10 PM TO 06:00 PM
POSTER TOUR LEADERS:
Govind Bhagat, New-york, United States
Hugo Penny, Sheffield, United Kingdom

P7-01 Use of Cladribine for Ulcerative Jejunitis: A Single-Center Experience in North America
Amelie Therrien, Boston, United States

P7-02 A capsule endoscopy and double-balloon enteroscopy sequential approach for early detection of complications in celiac disease: results of a prospective study
Luca Elli, Milano, Italy

P7-03 Small Bowel Adenocarcinoma as a complication of Celiac Disease: features of an old association in the new millennium
Giacomo Caio, Ferrara, Italy
<table>
<thead>
<tr>
<th>POSTER SESSIONS</th>
</tr>
</thead>
</table>
| **P7-04** | MicroRNA profiling in enteropathy associated T-cell lymphoma and refractory celiac disease  
Luca Elli, *Milano, Italy* |
| **P7-05** | Seronegative villous atrophy of unknown origin encompasses enteropathies with distinct clinical and genetic features and natural history  
Annalisa Schiepatti, *Sheffield, United States* |
| **P7-06** | Single Cell Analysis of Refractory Celiac Disease Type II  
Tessa Dieckman, *Leiden, Netherlands* |
| **P7-07** | Risk of Malignancy in Patients with Celiac Disease  
Manal Mahmoudi, *Rabat, Morocco* |
| **P7-08** | High Health Care Utilization in Non-Responsive Celiac Disease  
Shakira Yoosuf, *Boston, United Kingdom* |
| **P7-09** | Non-celiac villous atrophy in children: clinical and immunohistochemical features  
Renata Auricchio, *Naples, Italy* |
| **P7-12** | Alemtuzumab as treatment option for RCD type II? Report of two cases  
Federica Branchi, *Berlin, Germany* |
| **P7-13** | Ruxolitinib as tailored treatment for severe enterocolitis caused by STAT3 gain of function mutation  
Marianna Parlato, *Paris, France* |
| **P7-14** | Germline de novo mutation in immune checkpoint regulator PTPN2 causes very early onset autoimmune enteropathy by aberrant activation of JAK/STAT pathway  
Marianna Parlato, *Paris, France* |
| **P7-15** | Ulcerative jejunitis in celiac disease, a CELAC network study  
Julie Bruneau, *Paris, France* |
| **P7-16** | Body Mass Index and associated clinical variables in patients with Non-Celiac Wheat Sensitivity  
Antonio Carroccio, *Palermo, Italy* |
| **P7-17** | Gynecologic troubles in patients suffering with Non-Celiac Wheat Sensitivity  
Antonio Carroccio, *Palermo, Italy* |
| **P7-18** | A c-Myc-miRNAs circuit is deregulated in refractory celiac disease type 2 and EATL  
Valentina Vaira, *Milano, Italy* |
| **P7-19** | Enteropathy associated T-Cell Lymphoma incidence in refractory celiac disease type II patients treated with corticosteroids and/or chemotherapy  
Sherine Khater, *Paris, France* |
Research & Development in Gastroenterology and Hepatology

Innovative Drugs for bowel and liver diseases
Modern formulations and specially designed delivery systems ensure targeted release of the active drug.
PRACTICAL INFORMATION

Date
The congress will be held from Thursday, September 5th, 2019 to Saturday, September 7th, 2019

Venue
Paris Marriott Rive Gauche Hotel & Conference Center
17, boulevard Saint-Jacques
Paris, 75014 France

Getting to the venue

From Charles de Gaulle International Airport (CDG):
- RER B until Denfert-Rochereau then Metro Line 6 until Glaciere
- Estimated taxi fare: 55 EUR (one way)
- Bus service, fee: 17 EUR (one way)
- Subway service, fee: 10 EUR (one way)

From Paris/Orly Airport (ORY):
- ORLYBUS until Denfert-Rochereau then walk to the hotel / or Metro Line 6 until Glaciere
- Estimated taxi fare: 30 EUR (one way)
- Bus service, fee: 7.7 EUR (one way)
- Subway service, fee: 12.05 EUR (one way)

From train stations:
- Gare d’Austerlitz: Metro Line 5 until Place d’Italie then Metro Line 6 until Glaciere
- Gare de l’Est: Metro Line 5 until Place d’Italie then Metro Line 6 until Glaciere
- Gare de Lyon: Metro Line 14 until Bercy then Metro Line 6 until Glaciere
- Gare du Nord (Eurostar): RER Line B until Denfert-Rochereau and then Metro Line 6 until Glaciere
- Gare Montparnasse: Metro Line 6 until Glaciere
- Gare Saint Lazare: Metro Line 14 until Bercy then Metro Line 6 until Glaciere

Gala Dinner

Boat cruise on Seine river

Friday, September 6th, 2019, 07:30 pm - 10:00 pm
Bateaux Mouches, Port de la Conférence, PONT DE L’ALMA in the 8th district in Paris
ImmusanT is leveraging its Epitope-Specific Immuno-Therapy (ESIT) platform to discover, develop and deliver first-in-class peptide-based immune therapies to patients living with autoimmune diseases such as celiac disease, Type-1 diabetes and other human leukocyte antigen (HLA)-linked diseases.

ImmusanT is also using its technology and deep understanding of the immune system to develop new diagnostics that have the potential to provide highly specific and highly accurate diagnoses of auto-immune diseases. Our first diagnostic – GC2™ – is being developed to diagnose celiac disease through a simple in vitro blood test designed to measure T-cell markers.
Dr. Schär symposium

Friday, September 6th
9.15-10.30 am

Our mission:
We improve the lives of people with special nutritional needs

Dr. Schär symposium

18th International Celiac Disease Symposium

www.icds2019-paris.com

www.drschaer.com/fr/institute
Provention Bio, partnered with Amgen, is launching a Phase 2b trial to test PRV-015 (AMG 714) for diet non-responsive celiac disease.

Please join us on September 5th at 12:15 pm in Scène A+B+C for a symposium “Interleukin-15 (IL-15) in celiac disease and the therapeutic potential of the anti-IL-15 antibody PRV-015 (AMG 714)” featuring thought leaders in celiac disease.

To learn more about us, visit www.proventionbio.com